| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/01/2014 | EP2678026A1 Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
| 01/01/2014 | EP2678007A2 Protein nanocarriers for topical delivery |
| 01/01/2014 | EP1682573B1 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 01/01/2014 | CN103492877A Determination of the efficacy of an anti-mycobacterial vaccination |
| 01/01/2014 | CN103492583A Dual variable domain immunoglobulins and uses thereof |
| 01/01/2014 | CN103492574A Delivery of proteins using adeno-associated virus (aav) vectors |
| 01/01/2014 | CN103492566A Composition for predicting sensitivity to trastuzumab therapy in breast cancer patients and method using same |
| 01/01/2014 | CN103492565A FcgRIIb-specific Fc antibody |
| 01/01/2014 | CN103492419A Binding molecules capable of neutralizing the rabies virus, and uses thereof |
| 01/01/2014 | CN103492418A Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
| 01/01/2014 | CN103492413A Anti-TACE antibody molecules and their uses |
| 01/01/2014 | CN103492411A Mutant interleukin-2 polypeptides |
| 01/01/2014 | CN103492410A Bluetongue virus recombinant vaccines and uses thereof |
| 01/01/2014 | CN103492406A Use of chimeric antigen receptor-modified t cells to treat cancer |
| 01/01/2014 | CN103491979A Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
| 01/01/2014 | CN103491978A Therapeutic composition for treatment of glioblastoma |
| 01/01/2014 | CN103491957A Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| 01/01/2014 | CN103491952A Novel combination therapy for the treatment of cancer |
| 01/01/2014 | CN103484411A Avian Escherichia coli vaccine strain (NN strain) and application thereof |
| 01/01/2014 | CN103484397A Haemophilus parasuis engineering strain with hhdA gene deletion and without resistance maker and construction method thereof |
| 01/01/2014 | CN103483449A Two ScFv (Single Chain Variable Fragment ) antibodies, encoding genes and application thereof for preparing preparation for treating or preventing infectious bursal disease of chicken |
| 01/01/2014 | CN103483448A Antibody for specific binding with highly-pathogenic avian influenza virus |
| 01/01/2014 | CN103483447A Broad spectrum monoclonal antibodies or antigen binding fragments thereof of anti-HPV L1 protein, and applications thereof |
| 01/01/2014 | CN103483446A Broad spectrum neutralization monoclonal antibodies or antigen binding fragments thereof of anti-HPV L2 protein, and applications thereof |
| 01/01/2014 | CN103483441A Rhesus monkey NY-ESO-1 protein, coding gene, and applications thereof |
| 01/01/2014 | CN103483431A Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications |
| 01/01/2014 | CN103483430A Application of protein A1G_07050 to Rickettsia rickettsii-resisting immunoprotection |
| 01/01/2014 | CN103483421A Polypeptide used for treating HBV infection and related diseases, and antibodies thereof |
| 01/01/2014 | CN103480003A Novel HIV vaccine for triggering efficient CD4+T lymphocyte immune response |
| 01/01/2014 | CN103479998A Pegylated a beta FAB |
| 01/01/2014 | CN103479997A Preparation method for avian reovirus virus water-in-oil-in-water type inactivated vaccines |
| 01/01/2014 | CN103479996A Haemophilus parasuis (Hps) subunit vaccine composition and application |
| 01/01/2014 | CN103479995A Preparation method of mycoplasma gallisepticum and mycoplasma synoviae bivalent inactivated vaccine |
| 01/01/2014 | CN102716482B Highly pathogenic porcine reproductive and respiratory syndrome live vaccine diluted solution |
| 01/01/2014 | CN102657864B Immune adjuvant of foot-and-mouth disease vaccine and application of immune adjuvant |
| 01/01/2014 | CN102336834B Fully human TNFalpha-Fab antibody and its PEG antibody |
| 01/01/2014 | CN102335423B II type adenovirus live vector recombinant vaccine of dog for showing lyssa virus protective antigen by using spike |
| 01/01/2014 | CN102264394B Lipidated imidazoquinoline derivatives |
| 01/01/2014 | CN102257127B Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide |
| 01/01/2014 | CN101821403B Cell for use in the production of exogenous protein, and production process using the cell |
| 01/01/2014 | CN101454025B 抗体纯化 Antibody Purification |
| 01/01/2014 | CN101247825B Dr5抗体及其用途 Dr5 antibodies and their use |
| 01/01/2014 | CN101001646B Stabilized synthetic immunogen delivery system |
| 12/31/2013 | USRE44681 Compositions and methods for inhibiting growth of SMAD4-deficient cancers |
| 12/31/2013 | US8618276 Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues |
| 12/31/2013 | US8618275 Efficient cell culture system for hepatitis C virus genotype 5A |
| 12/31/2013 | US8618263 Antibodies against tissue factor pathway inhibitor (TFPI) |
| 12/31/2013 | US8618262 Monoclonal antibodies against dendritic cell receptor |
| 12/31/2013 | US8618252 Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| 12/31/2013 | US8618130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 12/31/2013 | US8618053 FGF21 mutants multimers and uses thereof |
| 12/31/2013 | US8617880 Chimeric toll-like receptor/MD-2 polypeptides and methods of use thereof |
| 12/31/2013 | US8617846 Tumor-specific recognition molecules |
| 12/31/2013 | US8617822 Method of inhibiting binding or activity of MIF by administering a MIF antagonist |
| 12/31/2013 | US8617821 Assay method for peptide specific T-cells |
| 12/31/2013 | US8617808 Cultispot assay |
| 12/31/2013 | US8617621 Composition for enhancing immunity containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as an active ingredient |
| 12/31/2013 | US8617575 Methods for conferring immunity against protozoans in an animal |
| 12/31/2013 | US8617574 Nontypable Haemophilus influenzae antigens |
| 12/31/2013 | US8617573 Botulinum neurotoxin B receptors and use thereof |
| 12/31/2013 | US8617572 Botulinum toxin treatments of depression |
| 12/31/2013 | US8617571 Suture line administration technique using botulinum toxin |
| 12/31/2013 | US8617570 Method for treating premature ejaculation with a botulinum neurotoxin |
| 12/31/2013 | US8617569 Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites |
| 12/31/2013 | US8617568 Pharmaceutical liquid composition of botulinum toxin with improved stability |
| 12/31/2013 | US8617566 Composition comprising VLP and amyloid beta peptide |
| 12/31/2013 | US8617565 Surface exposed Haemophilus influenzae protein (protein E; pE) |
| 12/31/2013 | US8617564 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| 12/31/2013 | US8617563 Antichlamydial agents |
| 12/31/2013 | US8617562 FOXM1 peptides and immunogenic compositions containing them |
| 12/31/2013 | US8617561 Immune disease medicament comprising a modulator of the binding between a heparin binding domain of thrombospondin-1 and a beta1 integrin |
| 12/31/2013 | US8617560 Peptides for vaccination against human CMV |
| 12/31/2013 | US8617559 Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| 12/31/2013 | US8617558 Camptothecin-binding moiety conjugates |
| 12/31/2013 | US8617557 Antibody fusion with IL-12 proteins with disrupted heparin-binding activity |
| 12/31/2013 | US8617556 Gram-positive bacteria specific binding compounds |
| 12/31/2013 | US8617555 Pharmaceutical compositions comprising activated-potentiated antibodies to human insulin receptor and endothelial nitric oxide (NO) synthase |
| 12/31/2013 | US8617554 Anti-human CD52 immunoglobulins |
| 12/31/2013 | US8617553 Use of goat serum for veterinary treatment |
| 12/31/2013 | US8617551 Methods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies |
| 12/31/2013 | US8617550 Treatment of vasculitis with IL-6 antagonist |
| 12/31/2013 | US8617549 Bispecific nanobodies as a therapeutic for alzheimer's disease |
| 12/31/2013 | US8617548 Methods of preventing or treating anthrax using anti-anthrax antibodies |
| 12/31/2013 | US8617547 Methods and compositions for diagnosing prostate cancer |
| 12/31/2013 | US8617546 Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody |
| 12/31/2013 | US8617545 Methods for use with BAFF antagonists |
| 12/31/2013 | US8617536 Prevotella histicola preparations and the treatment of autoimmune conditions |
| 12/31/2013 | US8617532 Therapeutic use of interferon-polymer conjugates |
| 12/31/2013 | US8617520 Cancer therapy |
| 12/31/2013 | US8617514 Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| 12/31/2013 | CA2722364C Melanoma antigens |
| 12/31/2013 | CA2617508C Virus-like particles as vaccines for paramyxovirus |
| 12/31/2013 | CA2596683C Conjugation of streptococcal capsular saccharides |
| 12/31/2013 | CA2548454C Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| 12/31/2013 | CA2523001C Therapeutic use of anti-cs1 antibodies |
| 12/31/2013 | CA2485847C Glucan-based vaccines |
| 12/31/2013 | CA2478371C Compositions and methods for generating an immune response |
| 12/31/2013 | CA2467908C Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages |
| 12/31/2013 | CA2246768C Uses of gdnf and gdnf receptor |
| 12/27/2013 | WO2013192604A1 Purification of virus like particles |